Semin Respir Crit Care Med 2013; 34(01): 032-043
DOI: 10.1055/s-0032-1333469
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Tuberculosis and HIV Coinfection

Jacob M. Gray
1   Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado
2   Current affiliation: Alaska Native Medical Center, Anchorage, Alaska
,
David L. Cohn
1   Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado
3   Denver Public Health, Denver Health and Hospital Authority, Denver, Colorado
› Author Affiliations
Further Information

Publication History

Publication Date:
04 March 2013 (online)

Abstract

The human immunodeficiency virus (HIV) pandemic has amplified the global burden of tuberculosis (TB), particularly in sub-Saharan Africa, where 82% of the world's TB/HIV coinfection exists. HIV infection significantly increases the risk of developing and dying from TB and was associated with 350,000 TB deaths in 2010. The diagnosis of HIV-associated TB is often challenging due to atypical clinical and radiographic manifestations, more frequent extrapulmonary disease, and higher rates of smear-negative pulmonary TB. Nucleic acid amplification tests, including the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA), improve our ability to rapidly diagnose both smear-negative and extrapulmonary TB. The standard 6-month anti-TB regimen is usually adequate for HIV coinfected persons, but intermittent dosing in the intensive phase should be avoided because of an increased risk of relapse with acquired rifamycin resistance. The comanagement of HIV and TB is challenging due to drug–drug interactions, overlapping drug toxicities, concerns about adherence, and the immune reconstitution inflammatory syndrome. However, the initiation of antiretroviral therapy (ART) during the course of TB treatment is necessary to improve survival, and the appropriate timing of ART is dependent on the level of immune suppression. Therefore, the management of TB must be well coordinated with HIV resources, prepared to rapidly diagnose HIV, assess immune status, and correctly treat both infections.

 
  • References

  • 1 World Health Organization, Stop TB Department. Global Tuberculosis Control 2011: WHO Report. Geneva, Switzerland: World Health Organization; 2011
  • 2 Selwyn PA, Hartel D, Lewis VA , et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320 (9) 545-550
  • 3 Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159 (3) 733-740
  • 4 Munsiff SS, Alpert PL, Gourevitch MN, Chang CJ, Klein RS. A prospective study of tuberculosis and HIV disease progression. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19 (4) 361-366
  • 5 Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191 (2) 150-158
  • 6 Markowitz N, Hansen NI, Hopewell PC , et al; The Pulmonary Complications of HIV Infection Study Group. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med 1997; 126 (2) 123-132
  • 7 Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23 (1) 75-80
  • 8 García de Viedma D, Marín M, Ruiz Serrano MJ, Alcalá L, Bouza E. Polyclonal and compartmentalized infection by Mycobacterium tuberculosis in patients with both respiratory and extrarespiratory involvement. J Infect Dis 2003; 187 (4) 695-699
  • 9 von Reyn CF, Kimambo S, Mtei L , et al. Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. Int J Tuberc Lung Dis 2011; 15 (8) 1087-1092
  • 10 Jones JL, Hanson DL, Dworkin MS, DeCock KM. Adult/Adolescent Spectrum of HIV Disease Group. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis 2000; 4 (11) 1026-1031
  • 11 Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359 (9323) 2059-2064
  • 12 Albalak R, O'Brien RJ, Kammerer JS , et al. Trends in tuberculosis/human immunodeficiency virus comorbidity, United States, 1993-2004. Arch Intern Med 2007; 167 (22) 2443-2452
  • 13 Granich R, Akolo C, Gunneberg C, Getahun H, Williams P, Williams B. Prevention of tuberculosis in people living with HIV. Clin Infect Dis 2010; 50 (Suppl. 03) S215-S222
  • 14 World Health Organization. Department of HIV/AIDS, Stop TB Department. Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings. Geneva, Switzerland: World Health Organization; 2011
  • 15 Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J RespirCrit Care Med 2005; 172 (1) 123-127
  • 16 Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190 (9) 1670-1676
  • 17 Cingolani A, Cozzi Lepri A, Castagna A , et al. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition. Clin Infect Dis 2012; 54 (6) 853-861
  • 18 Whalen CC, Nsubuga P, Okwera A , et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000; 14 (9) 1219-1228
  • 19 Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC. Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis 1987; 136 (3) 570-574
  • 20 Ackah AN, Coulibaly D, Digbeu H , et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet 1995; 345 (8950) 607-610
  • 21 Abdool Karim SS, Naidoo K, Grobler A , et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362 (8) 697-706
  • 22 Swaminathan S, Padmapriyadarsini C, Narendran G. HIV-associated tuberculosis: clinical update. Clin Infect Dis 2010; 50 (10) 1377-1386
  • 23 Burman WJ, Jones BE. Clinical and radiographic features of HIV-related tuberculosis. Semin Respir Infect 2003; 18 (4) 263-271
  • 24 Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148 (5) 1292-1297
  • 25 Perlman DC, el-Sadr WM, Nelson ET , et al; The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis 1997; 25 (2) 242-246
  • 26 Shafer RW, Kim DS, Weiss JP, Quale JM. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine (Baltimore) 1991; 70 (6) 384-397
  • 27 Shriner KA, Mathisen GE, Goetz MB. Comparison of mycobacterial lymphadenitis among persons infected with human immunodeficiency virus and seronegative controls. Clin Infect Dis 1992; 15 (4) 601-605
  • 28 Richter C, Perenboom R, Mtoni I , et al. Clinical features of HIV-seropositive and HIV-seronegative patients with tuberculous pleural effusion in Dar es Salaam, Tanzania. Chest 1994; 106 (5) 1471-1475
  • 29 Perenboom RM, Richter C, Swai AB , et al. Clinical features of HIV seropositive and HIV seronegative patients with tuberculous lymphadenitis in Dar es Salaam. Tuber Lung Dis 1995; 76 (5) 401-406
  • 30 Mtei L, Matee M, Herfort O , et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40 (10) 1500-1507
  • 31 Cain KP, McCarthy KD, Heilig CM , et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010; 362 (8) 707-716
  • 32 Rajasekaran S, Mahilmaran A, Annadurai S, Kumar S, Raja K. Manifestation of tuberculosis in patients with human immunodeficiency virus: a large Indian study. Ann Thorac Med 2007; 2 (2) 58-60
  • 33 Bem C. Human immunodeficiency virus-positive tuberculous lymphadenitis in Central Africa: clinical presentation of 157 cases. Int J Tuberc Lung Dis 1997; 1 (3) 215-219
  • 34 Archibald LK, den Dulk MO, Pallangyo KJ, Reller LB. Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania. Clin Infect Dis 1998; 26 (2) 290-296
  • 35 Clark TM, Burman WJ, Cohn DL, Mehler PS. Septic shock from Mycobacterium tuberculosis after therapy for Pneumocystis carinii. Arch Intern Med 1998; 158 (9) 1033-1035
  • 36 Berenguer J, Moreno S, Laguna F , et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med 1992; 326 (10) 668-672
  • 37 Török ME, Yen NT, Chau TT , et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)—associated tuberculous meningitis. Clin Infect Dis 2011; 52 (11) 1374-1383
  • 38 Lawn SD, Wood R. Poor prognosis of HIV-associated tuberculous meningitis regardless of the timing of antiretroviral therapy. Clin Infect Dis 2011; 52 (11) 1384-1387
  • 39 Yechoor VK, Shandera WX, Rodriguez P, Cate TR. Tuberculous meningitis among adults with and without HIV infection: experience in an urban public hospital. Arch Intern Med 1996; 156 (15) 1710-1716
  • 40 Dubé MP, Holtom PD, Larsen RA. Tuberculous meningitis in patients with and without human immunodeficiency virus infection. Am J Med 1992; 93 (5) 520-524
  • 41 Thwaites GE, Duc Bang N, Huy Dung N , et al. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J Infect Dis 2005; 192 (12) 2134-2141
  • 42 Vinnard C, Macgregor RR. Tuberculous meningitis in HIV-infected individuals. Curr HIV/AIDS Rep 2009; 6 (3) 139-145
  • 43 Marais S, Pepper DJ, Schutz C, Wilkinson RJ, Meintjes G. Presentation and outcome of tuberculous meningitis in a high HIV prevalence setting. PLoS ONE 2011; 6 (5) e20077
  • 44 Moreno S, Pacho E, López-Herce JA, Rodríguez-Créixems M, Martín-Scapa C, Bouza E. Mycobacterium tuberculosis visceral abscesses in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109 (5) 437
  • 45 Lupatkin H, Bräu N, Flomenberg P, Simberkoff MS. Tuberculous abscesses in patients with AIDS. Clin Infect Dis 1992; 14 (5) 1040-1044
  • 46 Keiper MD, Beumont M, Elshami A, Langlotz CP, Miller Jr WT. CD4 T lymphocyte count and the radiographic presentation of pulmonary tuberculosis: a study of the relationship between these factors in patients with human immunodeficiency virus infection. Chest 1995; 107 (1) 74-80
  • 47 Kisembo HN, Boon SD, Davis JL , et al. Chest radiographic findings of pulmonary tuberculosis in severely immunocompromised patients with the human immunodeficiency virus. Br J Radiol 2011; 85 (1014) e130-139
  • 48 Batungwanayo J, Taelman H, Dhote R, Bogaerts J, Allen S, Van de Perre P. Pulmonary tuberculosis in Kigali, Rwanda: impact of human immunodeficiency virus infection on clinical and radiographic presentation. Am Rev Respir Dis 1992; 146 (1) 53-56
  • 49 Yoo SD, Cattamanchi A, Den Boon S , et al. Clinical significance of normal chest radiographs among HIV-seropositive patients with suspected tuberculosis in Uganda. Respirology 2011; 16 (5) 836-841
  • 50 Elliott AM, Halwiindi B, Hayes RJ , et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg 1993; 96 (1) 1-11
  • 51 Davis JL, Worodria W, Kisembo H , et al. Clinical and radiographic factors do not accurately diagnose smear-negative tuberculosis in HIV-infected inpatients in Uganda: a cross-sectional study. PLoS ONE 2010; 5 (3) e9859
  • 52 Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369 (9578) 2042-2049
  • 53 World Health Organization. Stop TB Department, Department of HIV/AIDS, WHO Expert Group on Smear-negative Tuberculosis. Improving the Diagnosis and Treatment of Smear-Negative Pulmonary and Extrapulmonary Tuberculosis among Adults and Adolescents: Recommendations for HIV-Prevalent and Resource-Constrained Settings. Geneva, Switzerland: World Health Organization; 2007
  • 54 Monkongdee P, McCarthy KD, Cain KP , et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med 2009; 180 (9) 903-908
  • 55 Cattamanchi A, Davis JL, Worodria W , et al. Sensitivity and specificity of fluorescence microscopy for diagnosing pulmonary tuberculosis in a high HIV prevalence setting. Int J Tuberc Lung Dis 2009; 13 (9) 1130-1136
  • 56 Shea YR, Davis JL, Huang L , et al. High sensitivity and specificity of acid-fast microscopy for diagnosis of pulmonary tuberculosis in an African population with a high prevalence of human immunodeficiency virus. J Clin Microbiol 2009; 47 (5) 1553-1555
  • 57 Thammavong C, Paboriboune P, Bouchard B , et al. Bleach treatment of sputum samples aids pulmonary tuberculosis screening among HIV-infected patients in Laos. Int J Tuberc Lung Dis 2011; 15 (10) 1353-1358
  • 58 American Thoracic Society, Centers for Disease Control. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161 (4 Pt 1) 1376-1395
  • 59 Chien HP, Yu MC, Wu MH, Lin TP, Luh KT. Comparison of the BACTEC MGIT 960 with Löwenstein-Jensen medium for recovery of mycobacteria from clinical specimens. Int J Tuberc Lung Dis 2000; 4 (9) 866-870
  • 60 Leung E, Minion J, Benedetti A, Pai M, Menzies D. Microcolony culture techniques for tuberculosis diagnosis: a systematic review. Int J Tuberc Lung Dis 2012; 16 (1) 16-23
  • 61 World Health Organization. Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System: Policy Statement. Geneva, Switzerland: World Health Organization; 2011
  • 62 Boehme CC, Nabeta P, Hillemann D , et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363 (11) 1005-1015
  • 63 Theron G, Peter J, van Zyl-Smit R , et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011; 184 (1) 132-140
  • 64 Abimbola TO, Marston BJ, Date AA, Blandford JM, Sangrujee N, Wiktor SZ. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 60 (1) e1-e7
  • 65 Gandhi NR, Shah NS, Andrews JR , et al; Tugela Ferry Care and Research (TF CARES) Collaboration. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181 (1) 80-86
  • 66 Moore DA, Evans CA, Gilman RH , et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355 (15) 1539-1550
  • 67 Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32 (5) 1165-1174
  • 68 Bem C, Patil PS, Elliott AM, Namaambo KM, Bharucha H, Porter JD. The value of wide-needle aspiration in the diagnosis of tuberculous lymphadenitis in Africa. AIDS 1993; 7 (9) 1221-1225
  • 69 Bekedam HJ, Boeree M, Kamenya A , et al. Tuberculous lymphadenitis, a diagnostic problem in areas of high prevalence of HIV and tuberculosis. Trans R Soc Trop Med Hyg 1997; 91 (3) 294-297
  • 70 Daley P, Thomas S, Pai M. Nucleic acid amplification tests for the diagnosis of tuberculous lymphadenitis: a systematic review. Int J Tuberc Lung Dis 2007; 11 (11) 1166-1176
  • 71 Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?. J Clin Microbiol 2011; 49 (7) 2540-2545
  • 72 Cattamanchi A, Ssewenyana I, Davis JL , et al. Role of interferon-gamma release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection. BMC Infect Dis 2010; 10: 75
  • 73 Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; (1) CD000171
  • 74 Cohn DL. Subclinical tuberculosis in HIV-infected patients: another challenge for the diagnosis of tuberculosis in high-burden countries?. Clin Infect Dis 2005; 40 (10) 1508-1510
  • 75 Martinson NA, Barnes GL, Moulton LH , et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365 (1) 11-20
  • 76 Samandari T, Agizew TB, Nyirenda S , et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377 (9777) 1588-1598
  • 77 Holtz TH, Kabera G, Mthiyane T , et al. Use of a WHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort study. Lancet Infect Dis 2011; 11 (7) 533-540
  • 78 World Health Organization. Stop TB Departement. Treatment of Tuberculosis: Guidelines. 4th ed. Geneva, Switzerland: World Health Organization; 2010
  • 79 American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167 (4) 603-662
  • 80 Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medical Association of the Infectious Diseases Society of America. 2013. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.htm . In press
  • 81 Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364 (9441) 1244-1251
  • 82 Khan FA, Minion J, Pai M , et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50 (9) 1288-1299
  • 83 Mallory KF, Churchyard GJ, Kleinschmidt I, De Cock KM, Corbett EL. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2000; 4 (5) 455-462
  • 84 Lambert ML, Hasker E, Van Deun A, Roberfroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection?. Lancet Infect Dis 2003; 3 (5) 282-287
  • 85 Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358 (9294) 1687-1693
  • 86 Nettles RE, Mazo D, Alwood K , et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38 (5) 731-736
  • 87 Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005; 41 (1) 83-91
  • 88 Swaminathan S, Narendran G, Venkatesan P , et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181 (7) 743-751
  • 89 Burman W, Benator D, Vernon A , et al; Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173 (3) 350-356
  • 90 Vernon A, Burman W, Benator D, Khan A, Bozeman L. Tuberculosis Trials Consortium. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353 (9167) 1843-1847
  • 91 Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson Jr WD, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356 (9240) 1470-1474
  • 92 McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007; 196 (Suppl. 01) S63-S75
  • 93 Gandhi NR, Andrews JR, Brust JC , et al. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis 2012; 16 (1) 90-97
  • 94 Abdool Karim SS, Naidoo K, Grobler A , et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365 (16) 1492-1501
  • 95 Blanc FX, Sok T, Laureillard D , et al; CAMELIA (ANRS 1295–CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365 (16) 1471-1481
  • 96 Havlir DV, Kendall MA, Ive P , et al; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365 (16) 1482-1491
  • 97 Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10 (4) 251-261
  • 98 Manosuthi W, Sungkanuparph S, Thakkinstian A , et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006; 43 (2) 253-255
  • 99 Sinha S, Dhooria S, Kumar S , et al. The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment. AIDS Res Ther 2011; 8 (1) 41
  • 100 Ribera E, Pou L, Lopez RM , et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001; 28 (5) 450-453
  • 101 Autar RS, Wit FW, Sankote J , et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther 2005; 10 (8) 937-943
  • 102 Manosuthi W, Tantanathip P, Prasithisirikul W, Likanonsakul S, Sungkanuparph S. Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study. BMC Infect Dis 2008; 8: 136
  • 103 Boulle A, Van Cutsem G, Cohen K , et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300 (5) 530-539
  • 104 Shipton LK, Wester CW, Stock S , et al. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis 2009; 13 (3) 360-366
  • 105 Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32 (3) 194-209
  • 106 Boulanger C, Hollender E, Farrell K , et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49 (9) 1305-1311
  • 107 Sekar V, Lavreys L, Van de Casteele T , et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother 2010; 54 (10) 4440-4445
  • 108 Lin HC, Lu PL, Chang CH. Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra). Eye (Lond) 2007; 21 (12) 1540-1541
  • 109 Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis 2009; 48 (10) 1471-1474
  • 110 Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2012. http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm . Accessed January 10, 2013
  • 111 la Porte CJ, Colbers EP, Bertz R , et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48 (5) 1553-1560
  • 112 Nijland HM, L'homme RF, Rongen GA , et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008; 22 (8) 931-935
  • 113 Kassahun K, McIntosh I, Cui D , et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35 (9) 1657-1663
  • 114 Wenning LA, Hanley WD, Brainard DM , et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53 (7) 2852-2856
  • 115 Eron Jr JJ, Rockstroh JK, Reynes J , et al; QDMRK Investigators. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11 (12) 907-915
  • 116 Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5 (6) 361-373
  • 117 Meintjes G, Lawn SD, Scano F , et al; International Network for the Study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8 (8) 516-523
  • 118 Novak RM, Richardson JT, Buchacz K , et al; HIV Outpatient Study (HOPS) Investigators. Immune reconstitution inflammatory syndrome: incidence and implications for mortality. AIDS 2012; 26 (6) 721-730
  • 119 Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and “unmasking” of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177 (7) 680-685
  • 120 Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158 (1) 157-161
  • 121 Breen RA, Smith CJ, Bettinson H , et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59 (8) 704-707
  • 122 Wendel KA, Alwood KS, Gachuhi R, Chaisson RE, Bishai WR, Sterling TR. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 2001; 120 (1) 193-197
  • 123 Dibyendu D, Sarkar RN, Phaujdar S, Bhattacharyya K, Pal HK. Incidence and risk factors of immune reconstitution inflammatory syndrome in HIV-TB coinfected patients. Braz J Infect Dis 2011; 15 (6) 553-559
  • 124 Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005; 10 (3) 417-422
  • 125 Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21 (3) 335-341
  • 126 Burman W, Weis S, Vernon A , et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007; 11 (12) 1282-1289
  • 127 Huyst V, Lynen L, Bottieau E, Zolfo M, Kestens L, Colebunders R. Immune reconstitution inflammatory syndrome in an HIV/TB co-infected patient four years after starting antiretroviral therapy. Acta Clin Belg 2007; 62 (2) 126-129
  • 128 Pepper DJ, Marais S, Maartens G , et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009; 48 (11) e96-e107
  • 129 Meintjes G, Wilkinson RJ, Morroni C , et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24 (15) 2381-2390
  • 130 Luetkemeyer AF, Getahun H, Chamie G, Lienhardt C, Havlir DV. Tuberculosis drug development: ensuring people living with HIV are not left behind. Am J Respir Crit Care Med 2011; 184 (10) 1107-1113
  • 131 World Health Organization. Priority research questions for tuberculosis/human immunodeficiency virus (TB/HIV) in HIV-prevalent and resource-limited settings. Geneva, Switzerland: World Health Organization; 2010